DiamiR Biosciences, which is developing blood-based tests for neurodegenerative diseases, withdrew its plans for an initial public offering on Wednesday. It originally filed in June 2024 with a proposed deal size of $7 million.
The Monmouth Junction, NJ-based company was founded in 2009 and booked $1 million in revenue for the 12 months ended August 31, 2024. It had planned to list on the Nasdaq under the symbol DIMR. The Benchmark Company was set to be the sole bookrunner on the deal.
